Precision Genomic Medicine in Cystic Fibrosis

Overview

Journal Clin Transl Sci

Specialties Biomedical Engineering
General Medicine

Date 2015 Jun 16

PMID 26073768

Citations 13

Authors

Eugene H Chang

Joseph Zabner

Affiliations

Soon will be listed here.

Abstract

The successful application of precision genomic medicine requires an understanding of how a person's genome can influence his or her disease phenotype and how medical therapies can provide personalized therapy to one's genotype. In this review, we highlight advances in precision genomic medicine in cystic fibrosis (CF), a classic autosomal recessive genetic disorder. We discuss genotype-phenotype correlations in CF, genetic and environmental modifiers of disease, and pharmacogenetic therapies that target specific genetic mutations thereby addressing the primary defect of cystic fibrosis.

Citing Articles

From Serendipity to Precision: Integrating AI, Multi-Omics, and Human-Specific Models for Personalized Neuropsychiatric Care.

Tanaka M Biomedicines. 2025; 13(1).

PMID: 39857751 PMC: 11761901. DOI: 10.3390/biomedicines13010167.

Analysis of the genotypic profile and its relationship with the clinical manifestations in people with cystic fibrosis: study from a rare disease registry.

Rueda-Nieto S, Mondejar-Lopez P, Mira-Escolano M, Cutillas-Tolin A, Maceda-Roldan L, Arense-Gonzalo J Orphanet J Rare Dis. 2022; 17(1):222.

PMID: 35698092 PMC: 9195274. DOI: 10.1186/s13023-022-02373-y.

Clinical Phenotypes of Cystic Fibrosis Carriers.

Polgreen P, Comellas A Annu Rev Med. 2022; 73:563-574.

PMID: 35084992 PMC: 8884701. DOI: 10.1146/annurev-med-042120-020148.

Tripeptidyl Peptidase 1 (TPP1) Deficiency in a 36-Year-Old Patient with Cerebellar-Extrapyramidal Syndrome and Dilated Cardiomyopathy.

Lugowska A, Purzycka-Olewiecka J, Ploski R, Truszkowska G, Pronicki M, Felczak P Life (Basel). 2022; 12(1).

PMID: 35054396 PMC: 8779458. DOI: 10.3390/life12010003.

Paving the Way toward Personalized Medicine: Current Advances and Challenges in Multi-OMICS Approach in Autism Spectrum Disorder for Biomarkers Discovery and Patient Stratification.

Mesleh A, Abdulla S, El-Agnaf O J Pers Med. 2021; 11(1).

PMID: 33450950 PMC: 7828397. DOI: 10.3390/jpm11010041.

References

Zielenski J . Genotype and phenotype in cystic fibrosis. Respiration. 2000; 67(2):117-33. DOI: 10.1159/000029497. View

Houwen R, van der Doef H, Sermet I, Munck A, Hauser B, Walkowiak J . Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr. 2009; 50(1):38-42. DOI: 10.1097/MPG.0b013e3181a6e01d. View

Cohn J, Neoptolemos J, Feng J, Yan J, Jiang Z, Greenhalf W . Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. Hum Mutat. 2005; 26(4):303-7. DOI: 10.1002/humu.20232. View

Woodworth B, Ahn C, Flume P, Schlosser R . The delta F508 mutation in cystic fibrosis and impact on sinus development. Am J Rhinol. 2007; 21(1):122-7. DOI: 10.2500/ajr.2007.21.2905. View

Farrell P, Rosenstein B, White T, Accurso F, Castellani C, Cutting G . Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008; 153(2):S4-S14. PMC: 2810958. DOI: 10.1016/j.jpeds.2008.05.005. View

Wang X, Moylan B, Leopold D, Kim J, Rubenstein R, Togias A . Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA. 2000; 284(14):1814-9. DOI: 10.1001/jama.284.14.1814. View

Accurso F, Rowe S, Clancy J, Boyle M, Dunitz J, Durie P . Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010; 363(21):1991-2003. PMC: 3148255. DOI: 10.1056/NEJMoa0909825. View

Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E . Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011; 10 Suppl 2:S86-102. DOI: 10.1016/S1569-1993(11)60014-3. View

Clancy J, Rowe S, Accurso F, Aitken M, Amin R, Ashlock M . Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2011; 67(1):12-8. PMC: 3746507. DOI: 10.1136/thoraxjnl-2011-200393. View

10.

Chang E, Pezzulo A, Meyerholz D, Potash A, Wallen T, Reznikov L . Sinus hypoplasia precedes sinus infection in a porcine model of cystic fibrosis. Laryngoscope. 2012; 122(9):1898-905. PMC: 3449319. DOI: 10.1002/lary.23392. View

11.

Eckford P, Li C, Ramjeesingh M, Bear C . Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem. 2012; 287(44):36639-49. PMC: 3481266. DOI: 10.1074/jbc.M112.393637. View

12.

He L, Kota P, Aleksandrov A, Cui L, Jensen T, Dokholyan N . Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J. 2012; 27(2):536-45. PMC: 3545534. DOI: 10.1096/fj.12-216119. View

13.

Jih K, Hwang T . Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci U S A. 2013; 110(11):4404-9. PMC: 3600496. DOI: 10.1073/pnas.1215982110. View

14.

Bellin M, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J . Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes. 2013; 14(6):417-21. PMC: 3804832. DOI: 10.1111/pedi.12026. View

15.

Sosnay P, Siklosi K, Van Goor F, Kaniecki K, Yu H, Sharma N . Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013; 45(10):1160-7. PMC: 3874936. DOI: 10.1038/ng.2745. View

16.

Li W, Soave D, Miller M, Keenan K, Lin F, Gong J . Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum Genet. 2013; 133(2):151-61. DOI: 10.1007/s00439-013-1363-7. View

17.

Chang E . New insights into the pathogenesis of cystic fibrosis sinusitis. Int Forum Allergy Rhinol. 2013; 4(2):132-7. PMC: 3946531. DOI: 10.1002/alr.21252. View

18.

Raju S, Tate J, Peacock S, Fang P, Oster R, Dransfield M . Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis. Respir Res. 2014; 15:18. PMC: 3925354. DOI: 10.1186/1465-9921-15-18. View

19.

Berkhout M, van Rooden C, Rijntjes E, Fokkens W, el Bouazzaoui L, Heijerman H . Sinonasal manifestations of cystic fibrosis: a correlation between genotype and phenotype?. J Cyst Fibros. 2013; 13(4):442-8. DOI: 10.1016/j.jcf.2013.10.011. View

20.

Boyle M, Bell S, Konstan M, McColley S, Rowe S, Rietschel E . A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014; 2(7):527-38. DOI: 10.1016/S2213-2600(14)70132-8. View